Fig. 6: Accuracy evaluation for the mNGS assay. | Nature Communications

Fig. 6: Accuracy evaluation for the mNGS assay.

From: Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery

Fig. 6

Pie charts and 2 × 2 contingency tables showing the distribution of detected viruses and performance metrics. A mNGS against RVP testing, (B) mNGS testing against DTCA, and (C) RVP testing against DTCA. RVP testing using FDA IVD assays includes detection of respiratory syncytial virus, parainfluenza viruses 1–3, metapneumovirus, rhinovirus/enterovirus, influenza A virus, influenza B virus, and adenovirus. Discrepant samples that were mNGS-positive/RVP-negative or mNGS-negative/RVP-positive underwent orthogonal testing by targeted virus-specific PCR at the state public health laboratory and medical chart review for the most likely diagnosis by clinical adjudication. Abbreviations: mNGS metagenomic next-generation Sequencing, PCR polymerase chain reaction, RVP viral respiratory panel, DTCA discrepancy testing and clinical adjudication, PPA positive percent agreement, NPA negative percent agreement, OPA overall percent agreement, RSV respiratory syncytial virus, FDA Food and Drug Administration, IVD in vitro diagnostic.

Back to article page